Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial

Eric D. McCollum, Tisungane Mvalo, Michelle Eckerle, Andrew G. Smith, Davie Kondowe, Don Makonokaya, Dhananjay Vaidya, Veena Billioux, Alfred Chalira, Norman Lufesi, Innocent Mofolo, Mina Hosseinipour

Research output: Contribution to journalArticle

Abstract

Background: Pneumonia is the leading cause of death among children globally. Most pneumonia deaths in low-income and middle-income countries (LMICs) occur among children with HIV infection or exposure, severe malnutrition, or hypoxaemia despite antibiotics and oxygen. Non-invasive bubble continuous positive airway pressure (bCPAP) is considered a safe ventilation modality that might improve child pneumonia survival. bCPAP outcomes for high-risk African children with severe pneumonia are unknown. Since most child pneumonia hospitalisations in Africa occur in non-tertiary district hospitals without daily physician oversight, we aimed to examine whether bCPAP improves severe pneumonia mortality in such settings. Methods: This open-label, randomised, controlled trial was done in the general paediatric ward of Salima District Hospital, Malawi. We enrolled children aged 1–59 months old with WHO-defined severe pneumonia and either HIV infection or exposure, severe malnutrition, or an oxygen saturation of less than 90%. Children were randomly assigned 1:1 to low-flow nasal cannula oxygen or nasal bCPAP. Non-physicians administered care; the primary outcome was hospital survival. Primary analyses were by intention-to-treat and interim and adverse events analyses per protocol. This trial is registered with ClinicalTrials.gov, number NCT02484183, and is closed. Findings: We screened 1712 children for eligibility between June 23, 2015, and March 21, 2018. The data safety and monitoring board stopped the trial for futility after 644 of the intended 900 participants were enrolled. 323 children were randomly assigned to oxygen and 321 to bCPAP. 35 (11%) of 323 children who received oxygen died in hospital, as did 53 (17%) of 321 who received bCPAP (relative risk 1·52; 95% CI 1·02–2·27; p=0·036). 13 oxygen and 17 bCPAP patients lacked hospital outcomes and were considered lost to follow-up. Suspected adverse events related to treatment occurred in 11 (3%) of 321 children receiving bCPAP and 1 (<1%) of 323 children receiving oxygen. Four bCPAP and one oxygen group deaths were classified as probable aspiration episodes, one bCPAP death as probable pneumothorax, and six non-death bCPAP events included skin breakdown around the nares. Interpretation: bCPAP treatment in a paediatric ward without daily physician supervision did not reduce hospital mortality among high-risk Malawian children with severe pneumonia, compared with oxygen. The use of bCPAP within certain patient populations and non-intensive care settings might carry risk that was not previously recognised. bCPAP in LMICs needs further evaluation before wider implementation for child pneumonia care. Funding: Bill & Melinda Gates Foundation, International AIDS Society, Health Empowering Humanity.

Original languageEnglish (US)
Pages (from-to)964-974
Number of pages11
JournalThe Lancet Respiratory Medicine
Volume7
Issue number11
DOIs
StatePublished - Nov 2019

Fingerprint

Malawi
Continuous Positive Airway Pressure
Pneumonia
Randomized Controlled Trials
Oxygen
District Hospitals
Malnutrition
HIV Infections
Clinical Trials Data Monitoring Committees
Pediatrics
Medical Futility
Physicians
Patients' Rooms
Intention to Treat Analysis
Survival
Lost to Follow-Up
Pneumothorax
Child Care
Hospital Mortality

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi : an open label, randomised, controlled trial. / McCollum, Eric D.; Mvalo, Tisungane; Eckerle, Michelle; Smith, Andrew G.; Kondowe, Davie; Makonokaya, Don; Vaidya, Dhananjay; Billioux, Veena; Chalira, Alfred; Lufesi, Norman; Mofolo, Innocent; Hosseinipour, Mina.

In: The Lancet Respiratory Medicine, Vol. 7, No. 11, 11.2019, p. 964-974.

Research output: Contribution to journalArticle

McCollum, Eric D. ; Mvalo, Tisungane ; Eckerle, Michelle ; Smith, Andrew G. ; Kondowe, Davie ; Makonokaya, Don ; Vaidya, Dhananjay ; Billioux, Veena ; Chalira, Alfred ; Lufesi, Norman ; Mofolo, Innocent ; Hosseinipour, Mina. / Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi : an open label, randomised, controlled trial. In: The Lancet Respiratory Medicine. 2019 ; Vol. 7, No. 11. pp. 964-974.
@article{dac54f6bd0224b51b60ab2261b949f22,
title = "Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial",
abstract = "Background: Pneumonia is the leading cause of death among children globally. Most pneumonia deaths in low-income and middle-income countries (LMICs) occur among children with HIV infection or exposure, severe malnutrition, or hypoxaemia despite antibiotics and oxygen. Non-invasive bubble continuous positive airway pressure (bCPAP) is considered a safe ventilation modality that might improve child pneumonia survival. bCPAP outcomes for high-risk African children with severe pneumonia are unknown. Since most child pneumonia hospitalisations in Africa occur in non-tertiary district hospitals without daily physician oversight, we aimed to examine whether bCPAP improves severe pneumonia mortality in such settings. Methods: This open-label, randomised, controlled trial was done in the general paediatric ward of Salima District Hospital, Malawi. We enrolled children aged 1–59 months old with WHO-defined severe pneumonia and either HIV infection or exposure, severe malnutrition, or an oxygen saturation of less than 90{\%}. Children were randomly assigned 1:1 to low-flow nasal cannula oxygen or nasal bCPAP. Non-physicians administered care; the primary outcome was hospital survival. Primary analyses were by intention-to-treat and interim and adverse events analyses per protocol. This trial is registered with ClinicalTrials.gov, number NCT02484183, and is closed. Findings: We screened 1712 children for eligibility between June 23, 2015, and March 21, 2018. The data safety and monitoring board stopped the trial for futility after 644 of the intended 900 participants were enrolled. 323 children were randomly assigned to oxygen and 321 to bCPAP. 35 (11{\%}) of 323 children who received oxygen died in hospital, as did 53 (17{\%}) of 321 who received bCPAP (relative risk 1·52; 95{\%} CI 1·02–2·27; p=0·036). 13 oxygen and 17 bCPAP patients lacked hospital outcomes and were considered lost to follow-up. Suspected adverse events related to treatment occurred in 11 (3{\%}) of 321 children receiving bCPAP and 1 (<1{\%}) of 323 children receiving oxygen. Four bCPAP and one oxygen group deaths were classified as probable aspiration episodes, one bCPAP death as probable pneumothorax, and six non-death bCPAP events included skin breakdown around the nares. Interpretation: bCPAP treatment in a paediatric ward without daily physician supervision did not reduce hospital mortality among high-risk Malawian children with severe pneumonia, compared with oxygen. The use of bCPAP within certain patient populations and non-intensive care settings might carry risk that was not previously recognised. bCPAP in LMICs needs further evaluation before wider implementation for child pneumonia care. Funding: Bill & Melinda Gates Foundation, International AIDS Society, Health Empowering Humanity.",
author = "McCollum, {Eric D.} and Tisungane Mvalo and Michelle Eckerle and Smith, {Andrew G.} and Davie Kondowe and Don Makonokaya and Dhananjay Vaidya and Veena Billioux and Alfred Chalira and Norman Lufesi and Innocent Mofolo and Mina Hosseinipour",
year = "2019",
month = "11",
doi = "10.1016/S2213-2600(19)30243-7",
language = "English (US)",
volume = "7",
pages = "964--974",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi

T2 - an open label, randomised, controlled trial

AU - McCollum, Eric D.

AU - Mvalo, Tisungane

AU - Eckerle, Michelle

AU - Smith, Andrew G.

AU - Kondowe, Davie

AU - Makonokaya, Don

AU - Vaidya, Dhananjay

AU - Billioux, Veena

AU - Chalira, Alfred

AU - Lufesi, Norman

AU - Mofolo, Innocent

AU - Hosseinipour, Mina

PY - 2019/11

Y1 - 2019/11

N2 - Background: Pneumonia is the leading cause of death among children globally. Most pneumonia deaths in low-income and middle-income countries (LMICs) occur among children with HIV infection or exposure, severe malnutrition, or hypoxaemia despite antibiotics and oxygen. Non-invasive bubble continuous positive airway pressure (bCPAP) is considered a safe ventilation modality that might improve child pneumonia survival. bCPAP outcomes for high-risk African children with severe pneumonia are unknown. Since most child pneumonia hospitalisations in Africa occur in non-tertiary district hospitals without daily physician oversight, we aimed to examine whether bCPAP improves severe pneumonia mortality in such settings. Methods: This open-label, randomised, controlled trial was done in the general paediatric ward of Salima District Hospital, Malawi. We enrolled children aged 1–59 months old with WHO-defined severe pneumonia and either HIV infection or exposure, severe malnutrition, or an oxygen saturation of less than 90%. Children were randomly assigned 1:1 to low-flow nasal cannula oxygen or nasal bCPAP. Non-physicians administered care; the primary outcome was hospital survival. Primary analyses were by intention-to-treat and interim and adverse events analyses per protocol. This trial is registered with ClinicalTrials.gov, number NCT02484183, and is closed. Findings: We screened 1712 children for eligibility between June 23, 2015, and March 21, 2018. The data safety and monitoring board stopped the trial for futility after 644 of the intended 900 participants were enrolled. 323 children were randomly assigned to oxygen and 321 to bCPAP. 35 (11%) of 323 children who received oxygen died in hospital, as did 53 (17%) of 321 who received bCPAP (relative risk 1·52; 95% CI 1·02–2·27; p=0·036). 13 oxygen and 17 bCPAP patients lacked hospital outcomes and were considered lost to follow-up. Suspected adverse events related to treatment occurred in 11 (3%) of 321 children receiving bCPAP and 1 (<1%) of 323 children receiving oxygen. Four bCPAP and one oxygen group deaths were classified as probable aspiration episodes, one bCPAP death as probable pneumothorax, and six non-death bCPAP events included skin breakdown around the nares. Interpretation: bCPAP treatment in a paediatric ward without daily physician supervision did not reduce hospital mortality among high-risk Malawian children with severe pneumonia, compared with oxygen. The use of bCPAP within certain patient populations and non-intensive care settings might carry risk that was not previously recognised. bCPAP in LMICs needs further evaluation before wider implementation for child pneumonia care. Funding: Bill & Melinda Gates Foundation, International AIDS Society, Health Empowering Humanity.

AB - Background: Pneumonia is the leading cause of death among children globally. Most pneumonia deaths in low-income and middle-income countries (LMICs) occur among children with HIV infection or exposure, severe malnutrition, or hypoxaemia despite antibiotics and oxygen. Non-invasive bubble continuous positive airway pressure (bCPAP) is considered a safe ventilation modality that might improve child pneumonia survival. bCPAP outcomes for high-risk African children with severe pneumonia are unknown. Since most child pneumonia hospitalisations in Africa occur in non-tertiary district hospitals without daily physician oversight, we aimed to examine whether bCPAP improves severe pneumonia mortality in such settings. Methods: This open-label, randomised, controlled trial was done in the general paediatric ward of Salima District Hospital, Malawi. We enrolled children aged 1–59 months old with WHO-defined severe pneumonia and either HIV infection or exposure, severe malnutrition, or an oxygen saturation of less than 90%. Children were randomly assigned 1:1 to low-flow nasal cannula oxygen or nasal bCPAP. Non-physicians administered care; the primary outcome was hospital survival. Primary analyses were by intention-to-treat and interim and adverse events analyses per protocol. This trial is registered with ClinicalTrials.gov, number NCT02484183, and is closed. Findings: We screened 1712 children for eligibility between June 23, 2015, and March 21, 2018. The data safety and monitoring board stopped the trial for futility after 644 of the intended 900 participants were enrolled. 323 children were randomly assigned to oxygen and 321 to bCPAP. 35 (11%) of 323 children who received oxygen died in hospital, as did 53 (17%) of 321 who received bCPAP (relative risk 1·52; 95% CI 1·02–2·27; p=0·036). 13 oxygen and 17 bCPAP patients lacked hospital outcomes and were considered lost to follow-up. Suspected adverse events related to treatment occurred in 11 (3%) of 321 children receiving bCPAP and 1 (<1%) of 323 children receiving oxygen. Four bCPAP and one oxygen group deaths were classified as probable aspiration episodes, one bCPAP death as probable pneumothorax, and six non-death bCPAP events included skin breakdown around the nares. Interpretation: bCPAP treatment in a paediatric ward without daily physician supervision did not reduce hospital mortality among high-risk Malawian children with severe pneumonia, compared with oxygen. The use of bCPAP within certain patient populations and non-intensive care settings might carry risk that was not previously recognised. bCPAP in LMICs needs further evaluation before wider implementation for child pneumonia care. Funding: Bill & Melinda Gates Foundation, International AIDS Society, Health Empowering Humanity.

UR - http://www.scopus.com/inward/record.url?scp=85073519080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073519080&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(19)30243-7

DO - 10.1016/S2213-2600(19)30243-7

M3 - Article

C2 - 31562059

AN - SCOPUS:85073519080

VL - 7

SP - 964

EP - 974

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 11

ER -